Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
Roel H Wilting, Jan-Hermen Dannenberg

Abstract

Resistance of cancer cells to chemotherapeutics and emerging targeted drugs is a devastating problem in the treatment of cancer patients. Multiple mechanisms contribute to drug resistance such as increased drug efflux, altered drug metabolism, secondary mutations in drug targets, and activation of downstream or parallel signal transduction pathways. The rapid kinetics, the reversibility of acquired drug resistance and the absence of genetic mutations suggest an epigenetic basis for drug insensitivity. Similar to the cellular variance seen in the human body, epigenetic mechanisms, through reversible histone modifications and DNA methylation patterns, generate a variety of transcriptional states resulting in a dynamic heterogeneous tumor cell population. Consequently, epigenomes favoring survival in the presence of a drug by aberrant transcription of drug transporters, DNA-repair enzymes and pro-apoptotic factors render cytotoxic and targeted drugs ineffective and allow selection of rare drug-resistant tumor cells. Recent advances in charting cancer genomes indeed strongly indicate a role for epigenetic regulators in driving cancer, which may result in the acquisition of additional (epi)genetic modifications leading to drug resis...Continue Reading

References

Mar 13, 1995·American Journal of Medical Genetics·R W Miller, J H Rubinstein
Oct 11, 1994·Proceedings of the National Academy of Sciences of the United States of America·J G HermanW M Linehan
May 7, 1993·Science·L A AaltonenS R Hamilton
Dec 27, 1995·FEBS Letters·A E SeniorI L Urbatsch
Nov 21, 1997·Nature·B InbalA Kimchi
Apr 18, 1998·Proceedings of the National Academy of Sciences of the United States of America·V M RichonP A Marks
Dec 28, 1999·Molecular and Cellular Biology·S B McMahonM D Cole
Feb 17, 2000·The EMBO Journal·M A Martínez-BalbásT Kouzarides
Nov 9, 2000·The New England Journal of Medicine·M EstellerJ G Herman
Feb 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·A YouS L Schreiber
Jul 4, 2001·Nature Cell Biology·H M ChanN B La Thangue
Aug 3, 2001·Nature·S J NielsenT Kouzarides
Aug 22, 2001·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·P BorstL A Smets
Jan 10, 2002·Genes & Development·Adrian Bird
Jun 5, 2002·Annual Review of Biochemistry·P Borst, R Oude Elferink
Jun 28, 2002·Cell·Fred van LeeuwenDaniel E Gottschling
Oct 11, 2002·Nature·Sooryanarayana VaramballyArul M Chinnaiyan
Oct 18, 2002·International Journal of Cancer. Journal International Du Cancer·Emma J BryanIan G Campbell
Feb 26, 2003·Genes & Development·Joris PothofMarcel Tijsterman
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Päivi Peltomäki
Apr 15, 2003·Nature Medicine·Toshiyasu TaniguchiAlan D D'Andrea
Apr 19, 2003·Science·François GaudetRudolf Jaenisch
Aug 13, 2003·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shinichi ToyookaAdi F Gazdar

❮ Previous
Next ❯

Citations

Oct 12, 2012·Cancer Chemotherapy and Pharmacology·Nicolay V LitviakovVladimir M Perelmuter
Jun 19, 2013·Trends in Parasitology·Pedro Eduardo FerreiraSteven Richard Meshnick
Jul 25, 2013·Inorganic Chemistry·Isolda Romero-Canelón, Peter J Sadler
Mar 29, 2013·Nature Reviews. Cancer·Michael HölzelThomas Tüting
May 14, 2014·Molecular Medicine Reports·Ourania KoukouraStavros Sifakis
Feb 26, 2014·Journal of Gastroenterology·Sarah Schwitalla
May 29, 2015·Journal of Enzyme Inhibition and Medicinal Chemistry·Luana LuginiStefano Fais
Sep 15, 2012·Biochemical and Biophysical Research Communications·Jun-Feng ShiYu-Jie Sun
Nov 4, 2015·The Veterinary Journal·R KlopfleischA D Gruber
Sep 6, 2015·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Sophie TaylorStefano Fais
May 31, 2014·Scientific Reports·Barrie S RichSanford M Simon
Mar 13, 2014·Pharmacotherapy·Padmaja Mummaneni, Stacy S Shord
Mar 26, 2014·International Journal of Radiation Oncology, Biology, Physics·Jong Cheol LeeSang Yoon Kim
Mar 6, 2013·Pharmacology & Therapeutics·Dana BazzounRabih Talhouk
Aug 4, 2015·Nature Communications·Juan D ChavezJames E Bruce
Nov 26, 2015·Journal of Translational Medicine·Stefano Fais
May 12, 2015·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Liyan YangJianwen Liu
Jun 28, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Yajie WangJacob Hooker
Sep 23, 2014·Biochimica Et Biophysica Acta·Rita ShaknovichFranziska Michor
Feb 15, 2015·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Katsuhito NagaiHiroki Konishi
May 26, 2016·The American Journal of Chinese Medicine·Ching-Fen WuThomas Efferth
Dec 22, 2016·International Journal of Molecular Sciences·Marta Tellez-GabrielDominique Heymann
Jan 28, 2017·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Martina MontagnanaGiuseppe Lippi
May 10, 2017·International Journal of Cancer. Journal International Du Cancer·Keqiang ZhangDan J Raz
Apr 5, 2017·Current Opinion in Hematology·Pilar M DominguezRita Shaknovich
Apr 5, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Minhee KimDong-Eun Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Kevin G Chen, Branimir I Sikic
Birth Defects Research. Part C, Embryo Today : Reviews
Hoi-Hung CheungWai-Yee Chan
Journal of the National Cancer Institute
Xiaoxian LiJenny C Chang
Epigenomics
Tamer E Fandy, Steven D Gore
© 2022 Meta ULC. All rights reserved